Open Innovators Join free
News / 13 Nov 2026
Crunchbase News · 13 Nov 2026 · Collaborations & pilots

Johnson & Johnson Innovation co-leads USD 100 million Series C of Delix Therapeutics

Delix Therapeutics, a biotech in Bedford, Massachusetts, raised a USD 100 million Series C. Johnson & Johnson Innovation (JJDC) co-led the round with SV Health Investors' Dementia Discovery Fund. Delix develops optimised, psychedelic-derived compounds for psychiatric disorders.

Why it matters: Pharma CVCs co-lead with specialist funds in therapy areas where they want early access before clinical results.
Johnson & JohnsonBiotechHealth tech
Read the original at Crunchbase News

Related collaborations

Investment
Johnson & Johnson × Delix TherapeuticsDelix Therapeutics: J&J Innovation co-leads USD 100M Series C
AstraZeneca × BiomatterBiomatter: custom enzymes for AstraZeneca
BASF × BiomatterBiomatter: custom enzymes for BASF
Sanofi × BiomatterBiomatter: custom enzymes for Sanofi
All collaborations